Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.57 |
| ▸ | TOP1 | P11387 | 1/20 | 0.57 |
| ▸ | ESR1 | P03372 | 2/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | RXRA | P19793 | 1/20 | 0.53 |
| ▸ | RXRB | P28702 | 1/20 | 0.53 |
| ▸ | RXRG | P48443 | 1/20 | 0.53 |
| ▸ | FABP7 | O15540 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28123080 | 0.96 | RXRA (0.57) | KMT2AMAPTSMN1; SMN2SLC6A3TDP1 | |
| Hydrogen Sulfide SCHEMBL27779483 | 0.91 | KMT2A (0.56) | KMT2AMAPTSMN1; SMN2SLC6A3TDP1 | |
| SCHEMBL31517375 | 0.90 | KMT2A (0.68) | KMT2AMAPTSMN1; SMN2SLC6A3TDP1 | |
| SCHEMBL27898043 | 0.90 | RXRA (0.55) | KMT2AMAPTSMN1; SMN2SLC6A3TDP1 | |
| SCHEMBL11761673 | 0.87 | KMT2A (0.50) | KMT2AMAPTSMN1; SMN2SLC6A3TDP1 | |
| SCHEMBL2484009 | 0.86 | TOP1 (0.55) | KMT2AMAPTSMN1; SMN2SLC6A3TDP1 | |
| SCHEMBL27717755 | 0.84 | SLC6A3 (0.55) | KMT2AMAPTSMN1; SMN2SLC6A3TDP1 | |
| SCHEMBL725404 | 0.83 | KMT2A (0.76) | KMT2AMAPTSMN1; SMN2SLC6A3TDP1 | |
| SCHEMBL11761665 | 0.83 | LMNA (0.57) | KMT2AMAPTSMN1; SMN2SLC6A3TDP1 | |
| SCHEMBL30563023 | 0.82 | FABP3 (0.56) | MAPTSMN1; SMN2TDP1L3MBTL1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 258 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021011538-A1 | CAPSULE DOSAGE FORMS, METHODS OF PREPARATION AND METHODS OF USE THEREOF | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2021-01-21 | — | — | WO | claimed |
| JP-54078382-A | — | — | None | — | — | JP | disclosed |
| US-20240239759-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2024-07-18 | — | — | US | disclosed |
| CN-117986154-A | Antiparasitic compounds | 英特维特国际股份有限公司 | 2024-05-07 | — | — | CN | disclosed |
| EP-4284509-A1 | ANTIPARASITIC COMPOUNDS | Intervet International B.V. (NL) | 2023-12-06 | — | — | EP | disclosed |
| CN-116964031-A | Antiparasitic compounds | 英特维特国际股份有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-113166064-B | Cholinesterase inhibitor polymorph and application thereof | 长春华洋高科技有限公司 | 2023-04-11 | — | — | CN | disclosed |
| EP-2545777-B2 | Use of an isoxazoline composition as antiparasitic | INTERVET INT BV (NL) | 2023-01-18 | — | — | EP | disclosed |
| US-20220033539-A1 | CATALYST COMPONENTS FOR THE POLYMERIZATION OF OLEFINS | BASELL POLIOLEFINE ITALIA S.R.L. (IT) | 2022-02-03 | — | — | US | disclosed |
| US-20220000814-A1 | METHODS FOR TREATMENT OF PRADER-WILLI SYNDROME | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2022-01-06 | — | — | US | disclosed |
| WO-1992016206-A1 | THE USE OF 5-AMINOSALICYLIC ACID IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME - DIARRHEAL PHASE OR TYPE (IBS-D) | NORWICH EATON PHARMACEUTICALS INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| WO-1992016214-A1 | THE USE OF 5-AMINOSALICYLIC ACID IN THE TREATMENT OF IRRITABLE BOWEL SYNDROME - DIARRHEAL PHASE OR TYPE (IBS-D) | NORWICH EATON PHARMACEUTICALS INC. (US) | 1992-10-01 | — | — | WO | disclosed |
| US-5102576-A | Quick response properties | CHISSO CORPORATION (JP) | 1992-04-07 | — | — | US | disclosed |
| WO-1991017746-A1 | THE USE OF PHENYLPROPANOLAMINE AS A MUCUS SECRETAGOGUE IN THE UPPER AIRWAYS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1991-11-28 | — | — | WO | disclosed |
| EP-0427195-A2 | A ferroelectric liquid crystal composition | Chisso Corporation (JP) | 1991-05-15 | — | — | EP | disclosed |
| EP-0371448-A2 | Ferroelectric liquid crystal composition and liquid crystal display element | Chisso Corporation (JP) | 1990-06-06 | — | — | EP | disclosed |
| US-4882086-A | HIGH SPEED LIGHT SWITCHES | CHISSO CORPORATION (JP) | 1989-11-21 | — | — | US | disclosed |
| EP-0328330-A2 | Ferroelectric liquid crystal composition | CHISSO CORPORATION (JP) | 1989-08-16 | — | — | EP | disclosed |
| EP-0083886-A1 | Organic compound of the triple substituted biphenylyl benzoate type and process for its preparation | THOMSON-CSF (FR) | 1983-07-20 | — | — | EP | disclosed |
| JP-S5478382-A | LIQUID CRYSTAL COMPOSITION | ASAHI GLASS CO LTD | 1979-06-22 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000814-A1 | METHODS FOR TREATMENT OF PRADER-WILLI SYNDROME | MECP2, BHMT2, EBP | KMT2A 99/4885MAPT 3652/4885SMN1; SMN2 271/4885 |
| US-20240239759-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | KMT2A 799/4885MAPT 3469/4885SMN1; SMN2 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.